PLASMA FIBRINOGEN: A CARDIOVASCULAR RISK BIOMARKER IN TYPE 2 DIABETES MELLITUS SUBJECTS
Plasma fibrinogen
Abstract
Diabetes mellitus is a public health disease considered as metabolic and endocrine disorder that has been involved in cardiovascular episode. Fibrinogen, a glycoprotein has been incriminated as a risk factor of cardiovascular disease. This study aims to evaluate the plasma fibrinogen concentration of type 2 diabetes mellitus subjects in Agbor, Nigeria. A total of three hundred and ninety six (396) respondents were recruited into the study which comprises of three hundred and six (306) type 2 diabetes mellitus and ninety (90) age and sex matched apparently healthy subjects as controls. Five milliliters (5ml) of venous blood was collected aseptically with minimum stasis and dispensed into appropriate containers. Plasma fibrinogen concentration was evaluated using standard methods while statistical package for social sciences was employed to determine difference in mean ± standard deviation using student t test. Diabetes mellitus subjects exhibit a significantly (p<0.050) higher plasma fibrinogen than apparently healthy subjects when compared. Also, male diabetes mellitus show a significantly (p<0.05) higher plasma fibrinogen than female diabetes mellitus subjects when compared. In the same vein, male apparently control subjects show significantly (p<0.05) than female apparently control subjects when compared but there is no significant (p>0.05) difference observed in the age of all respondents. It is therefore pertinent to state that type 2 diabetes mellitus are prone to cardiovascular disease as well as the male gender. It is therefore recommended that plasma fibrinogen should be done regularly for diabetes mellitus subjects as well as life-style modification to prevent excess mortality
References
Adu E.M, Ukwamedu H.A and Oghagbon E.S (2015). Assessment of Cardiovascular Risk indices in Type 2 Diabetes Mellitus. Tropical Medicine and Surgery, 3 (2): 184. http://dx.doi.org/10.4172/2329-9088.1000184
Alvin CP. Diabetes Mellitus. In: Braunwald E, Faucei AS, Kasper DL, Hauser SL, Longo DL, Larry JJ (eds) (2001). Harrison‟s principles of internal medicine. 15th ed. New York: McGraw Hill Medical Publishing division; 2109-2137
Araoye, M.O. (2003). Research Methodology with Statistics for Health and Social Sciences. Ilorin: Nathadex Publishers
Bembde A.S (2012). A Study of Plasma Fibrinogen Level in Type-2 Diabetes Mellitus and its Relation to Glycemic Control. Indian Journal Hematology Blood Transfusion; 28(2):105–108 DOI 10.1007/s12288-011-0116-9.
Bruno G, Cavallo-perin P, Bargero G, Borra M, Errico N.D and Pagano G (1996). Association of fibrinogen with glycemic control and albumin excretion rate in patients with non-Insulin-dependent diabetes mellitus. Annals of Internal Medicine; 125:653-657.
Chatterjea M.N and Shinde R (2007). Plasma proteins – Chemistry and functions. In Textbook of Medical Biochemistry (7th Ed), Jaypee Brothers Medical Publishers Ltd, Pp : 99
Cook NS and Ubben D (1990). Fibrinogen as a major risk factor in cardiovascular disease. Trends Pharmaceutical Science; 11: 444-51.
Ernst E (1993). The role of fibrinogen as a cardiovascular risk factor. Atherosclerosis; 100: 1-12.
Ernst E and Ludwig KR (1993) Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of literature. Annals of Internal Medicine; 118:956–96
Gupta P, Bhambani P and Narang S (2016). Study of plasma fibrinogen level and its relation to glycemic control in type-2 diabetes mellitus patients attending diabetes clinic at a tertiary care teaching hospital in Madhya Pradesh, India. International Journal of Research in Medical Sciences, 4(9):3748-3754. DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20162613
Jain A, Gupta HL and Narayan S (2001) Hyperfibrinogenemia in patients of diabetes mellitus in relation to glycemic control and urinary albumin excretion rate. Journal Association of Physicians India 49:227–230
Kannel B.W, Wilson W.F, Belanger A.J, Gagnon Dr and D‟Agostino B.D (1987). Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. Journal of American Medical Association. 258:1183-1186.
Selvin E., Steffes M.W., Zhu H., Matsushita K., Wagenknecht L., Pankow J., Coresh J and Brancati F.L (2010). Glycated hemoglobin, diabetes, and cardiovascular risk in non-diabetic adults. New England Journal of Medicine, 362 (9): 800–811.
Thompson W.D and Smith E.B (1989). Atherosclerosis and coagulation system. Journal of Pathology; 159:97–106
Uloko A.E, Musa B.A., Ramalan M.A., Gezawa I.D., Puepet F.H., Uloko A.T., Borodo M.M., and Sada K.B (2018). Prevalence and Risk Factors for Diabetes Mellitus in Nigeria: A Systematic Review and Meta-Analysis. Diabetes Therapy, 9:1307–1316 https://doi.org/10.1007/s13300-018-0441-1
Vorster H.H, Jerling J.C, Step K, Badenhorst C.J, Slazus W, Venter C.S, Jooste P.L and Bourne L.T (1998). Plasma fibrinogen of black South Africans: the BRISK study. Public Health Nutrition: 1(3):169-176
Wilhelmsen L, Suardsudd K, Kristoffer KB, Larson B, Lennart W and Jibblin G (1984) Fibrinogen as a risk factor for stroke and myocardial infraction. New England Journal of Medicine; 311:501–505
Copyright (c) 2022 FUDMA JOURNAL OF SCIENCES
This work is licensed under a Creative Commons Attribution 4.0 International License.
FUDMA Journal of Sciences
